{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:04:13Z","timestamp":1779109453426,"version":"3.51.4"},"reference-count":12,"publisher":"Medical Association of Nippon Medical School","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2022,10,25]]},"DOI":"10.1272\/jnms.jnms.2022_89-503","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T22:08:34Z","timestamp":1631570914000},"page":"550-554","source":"Crossref","is-referenced-by-count":10,"title":["Maculopapular Drug Eruption Caused by Apalutamide: Case Report and Review of the Literature"],"prefix":"10.1272","volume":"89","author":[{"given":"Hiroki","family":"Katayama","sequence":"first","affiliation":[{"name":"Department of Dermatology, Nippon Medical School Tama Nagayama Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidehisa","family":"Saeki","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-Ichi","family":"Osada","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School Tama Nagayama Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: A novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72 (6):1494-503.","DOI":"10.1158\/0008-5472.CAN-11-3948"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378 (15):1408-18.","DOI":"10.1056\/NEJMoa1715546"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381 (1):13-24.","DOI":"10.1056\/NEJMoa1903307"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Uemura H, Koroki Y, Iwaki Y, et al. Correction to: Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study. BMC Urol. 2020;20 (1):1-12.","DOI":"10.1186\/s12894-020-00739-7"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30 (2):239-45.","DOI":"10.1038\/clpt.1981.154"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sagawa N, Watanabe Y, Mizuno Y, et al. A case of toxic epidermal necrolysis associated with apalutamide administration. J Cutan Immunol Allergy [Internet]. 2020;3:134-5. Available from: https:\/\/doi.org\/10.1002\/cia2.12138","DOI":"10.1002\/cia2.12138"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Endo Y, Oka A, Uehara A, et al. Fatal case of toxic epidermal necrolysis due to apalutamide used as a novel prostate cancer drug. J Dermatol [Internet]. 2020;47 (10):e359-60. Available from: https:\/\/doi.org\/10.1111\/1346-8138.15510","DOI":"10.1111\/1346-8138.15510"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kawakami Y, Mitsui M, Takamoto H, Yamamoto Y. Apalutamid-induced exanthematous drug eruption displaying spongiotic dermatitis successfully treated with dose reduction. Int J Dermatol [Internet]. February 2021. Available from: https:\/\/doi.org\/10.1111\/ijd.15420","DOI":"10.1111\/ijd.15420"},{"key":"9","unstructured":"9. Tohyama M. Two Cases of Apalutamide-induced Lichenoid Drug Rash. Jpn J Dermatol. 2020;130 (7):1653-7."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Gu\u00e9gan S, Bastuji-Garin S, Poszepczynska-Guign\u00e9 E, Roujeau J-C, Revuz J. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol. 2006;126 (2):272-6.","DOI":"10.1038\/sj.jid.5700068"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Langley RGB, Walsh N, Nevill T, Thomas L, Rowden G. Apoptosis is the mode of keratinocyte death in cutaneous graft-versus-host disease. J Am Acad Dermatol. 1996;35 (2 PART I):187-90.","DOI":"10.1016\/S0190-9622(96)90320-5"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ji C, Guha M, Zhu X, et al. Enzalutamide and apalutamide: In vitro chemical reactivity studies and activity in a mouse drug allergy model. Chem Res Toxicol. 2020;33 (1):211-22.","DOI":"10.1021\/acs.chemrestox.9b00247"}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/89\/5\/89_JNMS.2022_89-503\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T04:56:54Z","timestamp":1668229014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/89\/5\/89_JNMS.2022_89-503\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,25]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.jnms.2022_89-503","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"value":"1345-4676","type":"print"},{"value":"1347-3409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,25]]},"article-number":"JNMS.2022_89-503"}}